NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|47086915|ref|NP_998451|]
View 

leukotriene A-4 hydrolase [Danio rerio]

Protein Classification

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
leuko_A4_hydro super family cl37108
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
18-607 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


The actual alignment was detected with superfamily member TIGR02411:

Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 818.25  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    18 TKHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAKFELGAKHKFKGSPLEITLPFELSRG 97
Cdd:TIGR02411  13 TSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGSPLTISLPIATSKN 92
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    98 QHVIVEIEYETSPTATALQWLTPKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPreLVALMSALRDGQ 177
Cdd:TIGR02411  93 DEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP--LPVLMSGIRDGE 170
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   178 EP-DPSdssrvIYRFRQPVPMPSYLIAIVVGALESREIGPRSRVWSEKEYVDEAAYEF-AETETMLKTAESLAGPYVWGQ 255
Cdd:TIGR02411 171 TSnDPG-----KYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFeNDTEKFIKTAEDLIFPYEWGQ 245
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   256 YDVLVLPPSFPYGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGE 335
Cdd:TIGR02411 246 YDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGE 325
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   336 QLRQFKGIGGWKELHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELMGGPEVFMGFVKSYIQLFA 415
Cdd:TIGR02411 326 KTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEFDPFLRHYFKKFA 405
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   416 YGSVTTEEWKNYLFTYFKD--KVDILNKVDWNAWMHTPGMAPVRPQYDTTMADACTSLCQKWV-KAKEADLASFTEADVK 492
Cdd:TIGR02411 406 YKSLDTYQFKDALYEYFKDkkKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVdAAKADDLSSFNAKDIK 485
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   493 QLNSPQLIEFMALLLQED---PLPLSHVKKMGEVYKLNNIKNAEVRFRWLRICVKAQWEEAVPLALKMATEQGRMKFTRP 569
Cdd:TIGR02411 486 DFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADWLGTVGRMKFVRP 565
                         570       580       590
                  ....*....|....*....|....*....|....*...
gi 47086915   570 LFTEVyNFSKYSDEAVKTFKEIRGSLHPVTAMLVAKDL 607
Cdd:TIGR02411 566 GYRLL-NAFVDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
18-607 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 818.25  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    18 TKHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAKFELGAKHKFKGSPLEITLPFELSRG 97
Cdd:TIGR02411  13 TSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGSPLTISLPIATSKN 92
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    98 QHVIVEIEYETSPTATALQWLTPKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPreLVALMSALRDGQ 177
Cdd:TIGR02411  93 DEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP--LPVLMSGIRDGE 170
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   178 EP-DPSdssrvIYRFRQPVPMPSYLIAIVVGALESREIGPRSRVWSEKEYVDEAAYEF-AETETMLKTAESLAGPYVWGQ 255
Cdd:TIGR02411 171 TSnDPG-----KYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFeNDTEKFIKTAEDLIFPYEWGQ 245
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   256 YDVLVLPPSFPYGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGE 335
Cdd:TIGR02411 246 YDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGE 325
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   336 QLRQFKGIGGWKELHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELMGGPEVFMGFVKSYIQLFA 415
Cdd:TIGR02411 326 KTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEFDPFLRHYFKKFA 405
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   416 YGSVTTEEWKNYLFTYFKD--KVDILNKVDWNAWMHTPGMAPVRPQYDTTMADACTSLCQKWV-KAKEADLASFTEADVK 492
Cdd:TIGR02411 406 YKSLDTYQFKDALYEYFKDkkKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVdAAKADDLSSFNAKDIK 485
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   493 QLNSPQLIEFMALLLQED---PLPLSHVKKMGEVYKLNNIKNAEVRFRWLRICVKAQWEEAVPLALKMATEQGRMKFTRP 569
Cdd:TIGR02411 486 DFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADWLGTVGRMKFVRP 565
                         570       580       590
                  ....*....|....*....|....*....|....*...
gi 47086915   570 LFTEVyNFSKYSDEAVKTFKEIRGSLHPVTAMLVAKDL 607
Cdd:TIGR02411 566 GYRLL-NAFVDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
18-449 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 762.77  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  18 TKHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANG-QAAKFELGAKHKFKGSPLEITLPFELSR 96
Cdd:cd09599  13 TTHLDLDLTVDFDKKTISGSATLTLEVLQDGADELVLDTRDLDISSVTVNGgKELKFELGPRDPVLGSALTITLPSPLAK 92
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  97 GQHVIVEIEYETSPTATALQWLTPKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDG 176
Cdd:cd09599  93 GDTFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVTVPKGLTALMSALRTG 172
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 177 QEPDPSDSsrvIYRFRQPVPMPSYLIAIVVGALESREIGPRSRVWSEKEYVDEAAYEFAETETMLKTAESLAGPYVWGQY 256
Cdd:cd09599 173 EKEEAGTG---TYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFADTEKFLKAAEKLYGPYVWGRY 249
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 257 DVLVLPPSFPYGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGEQ 336
Cdd:cd09599 250 DLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYLERRILERLYGEE 329
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 337 LRQFKGIGGWKELHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELmGGPEVFMGFVKSYIQLFAY 416
Cdd:cd09599 330 YRQFEAILGWKDLQESIKEFGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQL-GGREVFDPFLRAYFKKFAF 408
                       410       420       430
                ....*....|....*....|....*....|....
gi 47086915 417 GSVTTEEWKNYLFTYF-KDKVDILNKVDWNAWMH 449
Cdd:cd09599 409 QSIDTEDFKDFLLEYFaEDKPEILDKIDWDAWLY 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
19-469 4.29e-104

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 327.37  E-value: 4.29e-104
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  19 KHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAKFElgakhkFKGSPLEITLPFELSRGQ 98
Cdd:COG0308  18 THYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTVDGKPLDFT------RDGERLTITLPKPLAPGE 91
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  99 HVIVEIEYETSP--TATALQWLTPkqtAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDG 176
Cdd:COG0308  92 TFTLEIEYSGKPsnGGEGLYRSGD---PPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGWVAVSNGNLVS 168
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 177 QEPDPSDssRVIYRFRQPVPMPSYLIAIVVGALESREIGPRS----RVWSEKEYVDEAAYEFAETETMLKTAESLAG-PY 251
Cdd:COG0308 169 ETELGDG--RTTWHWADTQPIPTYLFALAAGDYAVVEDTFASgvplRVYVRPGLADKAKEAFESTKRMLDFFEELFGvPY 246
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 252 VWGQYDVLVLPpSFPYGGMENPCLTFVTPTVLAGDR-------SLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYI 324
Cdd:COG0308 247 PFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADETatdadyeRRESVIAHELAHQWFGNLVTCADWDDLWLNEGFATYM 325
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 325 ERMIARCMEGEQ--LRQFKGIggwkelHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELMgGPEV 402
Cdd:COG0308 326 EQLFSEDLYGKDaaDRIFVGA------LRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHMLRTLL-GDEA 398
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 47086915 403 FMGFVKSYIQLFAYGSVTTEEWKNYL-------FTYFkdkvdilnkvdWNAWMHTPGMAPVRPQYDTTMADACT 469
Cdd:COG0308 399 FRAGLRLYFARHAGGNATTEDFLAALeeasgrdLSAF-----------FDQWLYQAGLPTLEVEYEYDADGKVT 461
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
494-607 7.30e-49

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 165.74  E-value: 7.30e-49
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   494 LNSPQLIEFMALLLQEDPLPLSHVKKMGEVYKLNNIKNAEVRFRWLRICVKAQWEEAVPLALKMATEQGRMKFTRPLFTE 573
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVYKLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYRA 80
                          90       100       110
                  ....*....|....*....|....*....|....
gi 47086915   574 VYNFSKysDEAVKTFKEIRGSLHPVTAMLVAKDL 607
Cdd:pfam09127  81 LNKVDR--DLAVETFEKNKDFYHPICRAMVEKDL 112
pepN PRK14015
aminopeptidase N; Provisional
194-323 3.68e-05

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 47.05  E-value: 3.68e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  194 PVPMPSYLIAIVVGALESRE--IGPRS------RVWSEKEYVDEAAYefAetetM--LKTA----ESlagpyVWG-QYD- 257
Cdd:PRK14015 184 PFPKPSYLFALVAGDLDVLEdtFTTRSgrevalEIYVEPGNLDKCDH--A----MdsLKKSmkwdEE-----RFGlEYDl 252
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  258 -----VLVlpPSFPYGGMENPCLT-FVTPTVLAG-----DRSLAG---VIAHEISHSWTGNLVTNRTWEHFWLNEGHTVY 323
Cdd:PRK14015 253 difmiVAV--DDFNMGAMENKGLNiFNSKYVLADpetatDADYERiesVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVF 330
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
18-607 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 818.25  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    18 TKHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAKFELGAKHKFKGSPLEITLPFELSRG 97
Cdd:TIGR02411  13 TSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERKEPLGSPLTISLPIATSKN 92
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    98 QHVIVEIEYETSPTATALQWLTPKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPreLVALMSALRDGQ 177
Cdd:TIGR02411  93 DEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP--LPVLMSGIRDGE 170
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   178 EP-DPSdssrvIYRFRQPVPMPSYLIAIVVGALESREIGPRSRVWSEKEYVDEAAYEF-AETETMLKTAESLAGPYVWGQ 255
Cdd:TIGR02411 171 TSnDPG-----KYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFeNDTEKFIKTAEDLIFPYEWGQ 245
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   256 YDVLVLPPSFPYGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGE 335
Cdd:TIGR02411 246 YDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERRIIGRLYGE 325
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   336 QLRQFKGIGGWKELHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELMGGPEVFMGFVKSYIQLFA 415
Cdd:TIGR02411 326 KTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEFDPFLRHYFKKFA 405
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   416 YGSVTTEEWKNYLFTYFKD--KVDILNKVDWNAWMHTPGMAPVRPQYDTTMADACTSLCQKWV-KAKEADLASFTEADVK 492
Cdd:TIGR02411 406 YKSLDTYQFKDALYEYFKDkkKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVdAAKADDLSSFNAKDIK 485
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   493 QLNSPQLIEFMALLLQED---PLPLSHVKKMGEVYKLNNIKNAEVRFRWLRICVKAQWEEAVPLALKMATEQGRMKFTRP 569
Cdd:TIGR02411 486 DFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADWLGTVGRMKFVRP 565
                         570       580       590
                  ....*....|....*....|....*....|....*...
gi 47086915   570 LFTEVyNFSKYSDEAVKTFKEIRGSLHPVTAMLVAKDL 607
Cdd:TIGR02411 566 GYRLL-NAFVDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
18-449 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 762.77  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  18 TKHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANG-QAAKFELGAKHKFKGSPLEITLPFELSR 96
Cdd:cd09599  13 TTHLDLDLTVDFDKKTISGSATLTLEVLQDGADELVLDTRDLDISSVTVNGgKELKFELGPRDPVLGSALTITLPSPLAK 92
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  97 GQHVIVEIEYETSPTATALQWLTPKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDG 176
Cdd:cd09599  93 GDTFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVTVPKGLTALMSALRTG 172
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 177 QEPDPSDSsrvIYRFRQPVPMPSYLIAIVVGALESREIGPRSRVWSEKEYVDEAAYEFAETETMLKTAESLAGPYVWGQY 256
Cdd:cd09599 173 EKEEAGTG---TYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFADTEKFLKAAEKLYGPYVWGRY 249
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 257 DVLVLPPSFPYGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGEQ 336
Cdd:cd09599 250 DLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYLERRILERLYGEE 329
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 337 LRQFKGIGGWKELHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELmGGPEVFMGFVKSYIQLFAY 416
Cdd:cd09599 330 YRQFEAILGWKDLQESIKEFGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQL-GGREVFDPFLRAYFKKFAF 408
                       410       420       430
                ....*....|....*....|....*....|....
gi 47086915 417 GSVTTEEWKNYLFTYF-KDKVDILNKVDWNAWMH 449
Cdd:cd09599 409 QSIDTEDFKDFLLEYFaEDKPEILDKIDWDAWLY 442
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
19-428 2.51e-124

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 373.32  E-value: 2.51e-124
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  19 KHLNLIYHVDFDRHVLKGKVALTVEVLEDKfSSLTLDSKDLKISKVSANGQAAKFelGAKHKFKGSPLEITLPFelSRGQ 98
Cdd:cd09595   1 YHYDLDLDVDFTTKTLNGTETLTVDASQVG-RELVLDLVGLTIHSVSVNGAAVDF--GEREHYDGEKLTIPGPK--PPGQ 75
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  99 HVIVEIEYETSPTATALQWLTpKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDGQE 178
Cdd:cd09595  76 TFTVRISFEAKPSKNLLGWLW-EQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKDLLASNGALVGEE 154
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 179 PDPSDssRVIYRFRQPVPMPSYLIAIVVGALESREIGPRSR------VWSEKEYVDEAAYEFAETETMLKTAE-SLAGPY 251
Cdd:cd09595 155 TGANG--RKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQprvglsVYSEPLQVDQAQYAFDATRAALAWFEdYFGGPY 232
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 252 VWGQYDVLVLPPsFPYGGMENPCLTFVTPTVLA-------GDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYI 324
Cdd:cd09595 233 PLPKYDLLAVPD-FNSGAMENPGLITFRTTYLLrskvtdtGARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYY 311
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 325 ERMIARCMEGEQLRQFKGIGGWKELHESVKQFGANNVLTnlvPNLHEVDTDEAFSSVPYEKGFALLYHLEELmGGPEVFM 404
Cdd:cd09595 312 ENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTST---PVRSPADPDVAYDGVTYAKGALVLRMLEEL-VGEEAFD 387
                       410       420
                ....*....|....*....|....
gi 47086915 405 GFVKSYIQLFAYGSVTTEEWKNYL 428
Cdd:cd09595 388 KGVQAYFNRHKFKNATTDDFIDAL 411
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
19-469 4.29e-104

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 327.37  E-value: 4.29e-104
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  19 KHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAKFElgakhkFKGSPLEITLPFELSRGQ 98
Cdd:COG0308  18 THYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTVDGKPLDFT------RDGERLTITLPKPLAPGE 91
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  99 HVIVEIEYETSP--TATALQWLTPkqtAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDG 176
Cdd:COG0308  92 TFTLEIEYSGKPsnGGEGLYRSGD---PPDGPPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVPAGWVAVSNGNLVS 168
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 177 QEPDPSDssRVIYRFRQPVPMPSYLIAIVVGALESREIGPRS----RVWSEKEYVDEAAYEFAETETMLKTAESLAG-PY 251
Cdd:COG0308 169 ETELGDG--RTTWHWADTQPIPTYLFALAAGDYAVVEDTFASgvplRVYVRPGLADKAKEAFESTKRMLDFFEELFGvPY 246
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 252 VWGQYDVLVLPpSFPYGGMENPCLTFVTPTVLAGDR-------SLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYI 324
Cdd:COG0308 247 PFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADETatdadyeRRESVIAHELAHQWFGNLVTCADWDDLWLNEGFATYM 325
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 325 ERMIARCMEGEQ--LRQFKGIggwkelHESVKQFGANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELMgGPEV 402
Cdd:COG0308 326 EQLFSEDLYGKDaaDRIFVGA------LRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHMLRTLL-GDEA 398
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....
gi 47086915 403 FMGFVKSYIQLFAYGSVTTEEWKNYL-------FTYFkdkvdilnkvdWNAWMHTPGMAPVRPQYDTTMADACT 469
Cdd:COG0308 399 FRAGLRLYFARHAGGNATTEDFLAALeeasgrdLSAF-----------FDQWLYQAGLPTLEVEYEYDADGKVT 461
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
19-428 4.95e-72

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 237.48  E-value: 4.95e-72
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  19 KHLNLIYHVDFDRHVLKGKVALTVEVLEDkFSSLTLDSKDLKISKVSANGQAAKFELGAKHKfkgspLEITLPFELSRGQ 98
Cdd:cd09603   4 LHYDLDLDYDPATKSLSGTATITFRATQD-LDSLQLDLVGLTVSSVTVDGVPAAFFTHDGDK-----LVITLPRPLAAGE 77
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  99 HVIVEIEYETSPTATALQWLTPKQTAGKKhPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDGQE 178
Cdd:cd09603  78 TFTVTVRYSGKPRPAGYPPGDGGGWEEGD-DGVWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTVVSNGRLVSTT 156
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 179 PDPSDssRVIYRFRQPVPMPSYLIAIVVGALESREIGPRSRV----WSEKEYVDEAAYEFAETETMLKTAESLAGPYVWG 254
Cdd:cd09603 157 TNGGG--TTTWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIplryYVPPGDAAKAKASFARTPEMLDFFEELFGPYPFE 234
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 255 QYDVLVLPPSfpYGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEG 334
Cdd:cd09603 235 KYGQVVVPDL--GGGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCADWADIWLNEGFATYAEWLWSEHKGG 312
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 335 EQlrqfkgiGGWKELHESvkqfgANNVLTNLVPNLHEVDTDEAFSSVPYEKGFALLYHLEELMgGPEVFMGFVKSYIQLF 414
Cdd:cd09603 313 AD-------AYRAYLAGQ-----RQDYLNADPGPGRPPDPDDLFDRDVYQKGALVLHMLRNLL-GDEAFFAALRAYLARY 379
                       410
                ....*....|....
gi 47086915 415 AYGSVTTEEWKNYL 428
Cdd:cd09603 380 AHGNVTTEDFIAAA 393
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
20-450 5.52e-59

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 203.58  E-value: 5.52e-59
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  20 HLNLIYHVDFDRHVLKGKVALTVEVLEDkFSSLTLDSKDLKISKVSANGQAAKFELGAK--HKFKGSPLEITLPFELSRG 97
Cdd:cd09601   2 HYDLTLTPDLENFTFSGSVTITLEVLEP-TDTIVLHAKDLTITSASLTLKGGSGIIEVTvvTDEETEFLTITLDETLPPG 80
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  98 QHVIVEIEY--ETSPTATALQWLTPKQTAGKKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVAL--MSAL 173
Cdd:cd09601  81 ENYTLSIEFtgKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALsnMPPV 160
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 174 rdgqEPDPSDSSRVIYRFRQPVPMPSYLIAIVVGALESREI----GPRSRVWSEKEYVDEAAYEFAETETMLKTAESLAG 249
Cdd:cd09601 161 ----ESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESttksGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 250 -PYVWGQYDVLVLPpSFPYGGMENP-CLTFVTPTVLAGD--------RSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEG 319
Cdd:cd09601 237 iPYPLPKLDLVAIP-DFAAGAMENWgLITYRETALLYDPktssasdkQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEG 315
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 320 HTVYIERMIARCMEGEqlrqfkgiggWKelheSVKQFGANNVLTNL------------VPNLHEVDTDEAFSSVPYEKGF 387
Cdd:cd09601 316 FATYMEYLAVDKLFPE----------WN----MWDQFVVDELQSALeldslasshpieVPVESPSEISEIFDAISYSKGA 381
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|...
gi 47086915 388 ALLYHLEELMgGPEVFMGFVKSYIQLFAYGSVTTEEwknyLFTYFKDKVDILNKVDWNAWMHT 450
Cdd:cd09601 382 SVLRMLENFL-GEEVFRKGLRKYLKKHAYGNATTDD----LWEALQEASGESKPLDVKEIMDS 439
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
25-447 2.78e-49

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 177.32  E-value: 2.78e-49
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  25 YHVDFD----RHVLKGKVALTVEVLEDKfSSLTLDSKDLKISKVSANGQAAKFELGAKHKfkgspleITLPFELSRGQHV 100
Cdd:cd09602  18 YDLDLDltegAETFRGTVTIRFTLREPG-ASLFLDFRGGEVKSVTLNGRPLDPSAFDGER-------ITLPGLLKAGENT 89
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 101 iVEIEYETSPTAT--ALQWLTPKQTagkKHPYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMSALRDGQE 178
Cdd:cd09602  90 -VVVEFTAPYSSDgeGLHRFVDPAD---GETYLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPADWTVISNGPETSTE 165
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 179 PDpsdSSRVIYRFRQPVPMPSYLIAIVVG---ALESREIGPRSRVW---SEKEYVDEAAYEFAETETMLKTAESLAG-PY 251
Cdd:cd09602 166 EA---GGRKRWRFAETPPLSTYLFAFVAGpyhRVEDEHDGIPLGLYcreSLAEYERDADEIFEVTKQGLDFYEDYFGiPY 242
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 252 VWGQYDvLVLPPSFPYGGMENP-CLTF---------VTPTVLAGdrsLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHT 321
Cdd:cd09602 243 PFGKYD-QVFVPEFNFGAMENPgAVTFresylfreePTRAQRLR---RANTILHEMAHMWFGDLVTMKWWDDLWLNESFA 318
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 322 VYierMIARCMEGeqlrQFKGIGGWKELHESVKQF--------GANNVLTNLvpnlheVDTDEAFS---SVPYEKGFALL 390
Cdd:cd09602 319 DF---MAAKALAE----ATPFTDAWLTFLLRRKPWayradqlpTTHPIAQDV------PDLEAAGSnfdGITYAKGASVL 385
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 391 YHLEELMgGPEVFMGFVKSYIQLFAYGSVTteewknylftyFKDKVDILNKV---DWNAW 447
Cdd:cd09602 386 KQLVALV-GEEAFRAGLREYFKKHAYGNAT-----------LDDLIAALDEAsgrDLSAW 433
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
494-607 7.30e-49

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 165.74  E-value: 7.30e-49
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   494 LNSPQLIEFMALLLQEDPLPLSHVKKMGEVYKLNNIKNAEVRFRWLRICVKAQWEEAVPLALKMATEQGRMKFTRPLFTE 573
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVYKLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYRA 80
                          90       100       110
                  ....*....|....*....|....*....|....
gi 47086915   574 VYNFSKysDEAVKTFKEIRGSLHPVTAMLVAKDL 607
Cdd:pfam09127  81 LNKVDR--DLAVETFEKNKDFYHPICRAMVEKDL 112
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
231-450 8.34e-48

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 166.70  E-value: 8.34e-48
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   231 AYEFAEtETMLKTAESLAGPYVWGQYDVLVLPpSFPYGGMENPCLTFVTPTVLAGD---------RSLAGVIAHEISHSW 301
Cdd:pfam01433   2 ALEITV-KLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915   302 TGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGEQ--LRQFKGIGGWKELHESVKQfGANNVLTNLvpnLHEVDTDEAFS 379
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWniWEQFLLDEVQNAMARDALD-SSHPITQNV---NDPSEIDDIFD 155
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 47086915   380 SVPYEKGFALLYHLEELMgGPEVFMGFVKSYIQLFAYGSVTTEEWKNYLFTYfkdkvdiLNKVDWNAWMHT 450
Cdd:pfam01433 156 AIPYEKGASVLRMLETLL-GEEVFQKGLRSYLKKFQYGNATTEDLWDALSEA-------SGPLDVDSFMDT 218
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
20-201 6.51e-28

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 110.51  E-value: 6.51e-28
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    20 HLNLIYHVDFDRHVLKGKVALTVEVLEDKfSSLTLDSKDLKISKVSANGQAAKFELGAKHKF---KGSPLEITLPFELSR 96
Cdd:pfam17900   4 HYDLDLKIDLKNFTFSGSVTITLQLNNAT-NVIVLHASDLTIRSISLSDEVTSDGVPADFTEdqkDGEKLTIVLPETLNQ 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915    97 GQHVIVEIEYET--SPTATALQWLTPKQTAGKKHpYLFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALmSALR 174
Cdd:pfam17900  83 TGPYTLEIEYSGelNDSMTGFYRSTYTDNGEKKV-LVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTAL-SNMP 160
                         170       180
                  ....*....|....*....|....*..
gi 47086915   175 DGQEpDPSDSSRVIYRFRQPVPMPSYL 201
Cdd:pfam17900 161 VIAS-EPLENGWVITTFEQTPKMSTYL 186
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
234-328 3.08e-23

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 94.47  E-value: 3.08e-23
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 234 FAETETMLKTAESLAG-----PYVWGQYDVLVLPP---SFPYGGMENP-CLTFVTPTVLAGDRSLAGVIAHEISHSWTGN 304
Cdd:cd09594   1 TSYAHETYKYYEELLGrtsfrYPVSPIYSLLVYPAyveVNAYNAMWIPsTNIFYGAGILDTLSGTIDVLAHELTHAFTGQ 80
                        90       100
                ....*....|....*....|....*
gi 47086915 305 LVTN-RTWEHFWLNEGHTVYIERMI 328
Cdd:cd09594  81 FSNLmYSWSSGWLNEGISDYFGGLV 105
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
58-426 2.09e-22

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 100.43  E-value: 2.09e-22
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  58 DLKISKVSANGQAAKFELgakhKFKGSPLEITLPFELSRGQHVIVEIEYET------------SPTATALQWLtPK---- 121
Cdd:cd09604  65 GIDIDSVKVNGKGLKLEV----TLTITRLKLALPLPLKPGESVTVEIDFTVklpeqggrfgydGDEYNLAQWY-PKlavy 139
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 122 QTAG-KKHPYLFSQcqathcrtmvpcqdtpsvkHTYYAQVS-------VPRELVALMSALRdgQEPDPSDSSRVIYRFRQ 193
Cdd:cd09604 140 DDGGwNTDPYYGRG-------------------EFFYSDFGdydvtitVPKNYVVAATGEL--QNPEEVLDGTKTWHFKA 198
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 194 P-------VPMPSYLIaivvgaLESREIGPRSRVWSEKEYVDEAAYEFAETETMLKTAESLAGPYVWGQYDVlVLPPSFp 266
Cdd:cd09604 199 EnvrdfawAASPDFVV------DAATVDGVTVNVYYLPENAEAAERALEYAKDALEFFSEKFGPYPYPELDV-VQGPFG- 270
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 267 YGGMENPCLTFVTPTVLAGDRSLAGVIAHEISHSWTGNLVTNRTWEHFWLNEGHTVYIERMIARCMEGeqlrqfKGIGGW 346
Cdd:cd09604 271 GGGMEYPGLVFIGSRLYDPKRSLEGVVVHEIAHQWFYGIVGNDERREPWLDEGLATYAESLYLEEKYG------KEAADE 344
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 347 KELHESVKQFGANNVLTNLVPnLHEVDTDEAFSSVPYEKGFALLYHLEELMgGPEVFMGFVKSYIQLFAYGSVTTEEWKN 426
Cdd:cd09604 345 LLGRRYYRAYARGPGGPINLP-LDTFPDGSYYSNAVYSKGALFLEELREEL-GDEAFDKALREYYRRYKFKHPTPEDFFR 422
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
19-323 3.73e-18

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 87.19  E-value: 3.73e-18
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  19 KHLNLIYHVDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAkfelgAKHKFKGSPLEITLPFELSRGQ 98
Cdd:cd09600  10 DHVDLDFDLDDDETIVTSRLRVRRNPDSGEGAPLVLDGEDLELLSVKIDGKPL-----SPSDYTLDEEGLTIKNVPDRFV 84
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  99 hviVEIEYETSPTA-TALQWLtpkqtagkkhpY-----LFSQCQATHCRTMVPCQDTPSVKHTYYAQVSVPRELVALMsa 172
Cdd:cd09600  85 ---LEIEVRINPAAnTSLEGL-----------YksggiLCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEKYPVL-- 148
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 173 LRDGQ--EPDPSDSSRVIYRFRQPVPMPSYLIAIVVGALESRE--IGPRS------RVWSEKEYVDEAAYEFAEtetmLK 242
Cdd:cd09600 149 LSNGNliEEGELPNGRHFAVWEDPFPKPSYLFALVAGDLGSVEdtFTTKSgrkvklRIYVEPGNEDKCHHAMES----LK 224
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 243 TA----ESlagpyVWG-QYDV----LVLPPSFPYGGMENPCLT-FVTPTVLAG-----DRSLA---GVIAHEISHSWTGN 304
Cdd:cd09600 225 KAmkwdEE-----RFGlEYDLdlfnIVAVDDFNMGAMENKGLNiFNSKYVLADpetatDADYErieSVIAHEYFHNWTGN 299
                       330
                ....*....|....*....
gi 47086915 305 LVTNRTWEHFWLNEGHTVY 323
Cdd:cd09600 300 RVTCRDWFQLSLKEGLTVF 318
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
27-211 3.42e-12

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 69.18  E-value: 3.42e-12
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  27 VDFDRHVLKGKVALTVEVLEDKFSSLTLDSKDLKISKVSANGQAAKFE---------------LGAKHKFK--------- 82
Cdd:cd09839  10 VDFANRSIIGYTEITIVPTSPDLRTIRLNCRQCKIKSVTVNGVEAEFTyndplqnldlsdntdVNAHHELKrklaaalae 89
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  83 ---GSP-LEITLPFEL----------------------SRGQHVI-VEIEYETSPTATALQWLTPKQTAGKKHPYLFSQC 135
Cdd:cd09839  90 pdeGNEeLVISLPPSVkielqdpnsastqattsspdtsEDEFTPLtIRIEYSLKNPRDGLHFVGPDEGGDKRYPHVYTTN 169
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915 136 QATHC--RTMVPCQDTPSVKHTYYAQVSVPR-----------------------------ELVALMSALRDGQEPDPSDS 184
Cdd:cd09839 170 SPLPGsaRCWFPCVDSLWERCTWELEITVPRtlgdagrpplagskededdddlteedkelEMVVVCSGDLVEQVVHPEDP 249
                       250       260
                ....*....|....*....|....*..
gi 47086915 185 SRVIYRFRQPVPMPSYLIAIVVGALES 211
Cdd:cd09839 250 SKKTFSFSLSNPTSAQHIGFAVGPFEI 276
pepN PRK14015
aminopeptidase N; Provisional
194-323 3.68e-05

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 47.05  E-value: 3.68e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  194 PVPMPSYLIAIVVGALESRE--IGPRS------RVWSEKEYVDEAAYefAetetM--LKTA----ESlagpyVWG-QYD- 257
Cdd:PRK14015 184 PFPKPSYLFALVAGDLDVLEdtFTTRSgrevalEIYVEPGNLDKCDH--A----MdsLKKSmkwdEE-----RFGlEYDl 252
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 47086915  258 -----VLVlpPSFPYGGMENPCLT-FVTPTVLAG-----DRSLAG---VIAHEISHSWTGNLVTNRTWEHFWLNEGHTVY 323
Cdd:PRK14015 253 difmiVAV--DDFNMGAMENKGLNiFNSKYVLADpetatDADYERiesVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVF 330
Transglut_i_TM pfam14400
Inactive transglutaminase fused to 7 transmembrane helices; A family of inactive ...
455-510 1.84e-04

Inactive transglutaminase fused to 7 transmembrane helices; A family of inactive transglutaminases fused to seven transmembrane helices. The transglutaminase domain is predicted to be extracellularly located. Members of this family are associated in gene neighbourhoods with a pepsin-like peptidase and an ATP-grasp of the RimK-family. The ATP-grasp is predicted to modify the 7TM protein or a cofactor that interacts with it.


Pssm-ID: 433934  Cd Length: 161  Bit Score: 42.22  E-value: 1.84e-04
                          10        20        30        40        50
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 47086915   455 PVRPQYDTTMADACTSLCQKwVKAKEADLASFTEADVKQLNSPQLIEFMALLLQED 510
Cdd:pfam14400 107 PEPPDWPEPEATAAEQLLEE-ARARSADNLSFARELIKRLNAPDPDQNAALLLSDN 161
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH